A Phase 1 dose exploration study evaluating HPN601
Latest Information Update: 23 Nov 2022
At a glance
- Drugs HPN 601 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 23 Nov 2022 New trial record
- 14 Nov 2022 According to a Harpoon Therapeutics media release, expects to be ready to file an IND in the first half of 2023 to enable this study.